Important regulatory milestone marks development into clinical-stage building of next-generation RNAi remedy that includes an leading edge, built-in systemic remedy supply manner concentrated on extremely prevalent KRAS-driven cancers with vital unmet clinical want
Corporate reported sturdy sure preclinical find out about effects demonstrating vital anti-tumor task in more than one fashions and introduced a success finishing touch of toxicology research, and positive regulatory engagement supporting the Section 2/3 trial design
Silexion expects to start up human scientific trials in the second one quarter of 2026
Grand Cayman, Cayman Islands, March 24, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology corporate, as of late introduced that it has won formal approval from the Israeli Ministry of Well being to start up its Section 2/3 scientific trial comparing SIL204 for the remedy of in the community complicated pancreatic most cancers, following sure preclinical effects that demonstrated vital anti-tumor task in mulitple fashions along a success finishing touch of toxicology research.
This approval represents a significant regulatory milestone and a vital development for the Corporate, enabling the transition of SIL204 into human scientific analysis and positioning Silexion as a clinical-stage biotechnology corporate curious about KRAS-driven cancers.
SIL204 is designed to silence KRAS mutations, which can be found in over 90% of pancreatic cancers and are widely known as one of the difficult goals in oncology. Not like mutation-specific approaches, SIL204 is engineered to focus on a large vary of KRAS mutations, supporting its doable applicability throughout more than one high-value most cancers indications.
The approval follows a chain of primary sure trends completed via the Corporate, together with sturdy sure anti-tumor task demonstrated in more than one preclinical fashions, a success finishing touch of toxicology research, and positive regulatory engagement supporting the Section 2/3 trial design. In combination, those achievements have enabled SIL204 to advance towards clinical-stage building. The Corporate additionally plans to put up a Section 2/3 scientific trial software in Germany via the top of this present quarter, with further regulatory filings around the Ecu Union deliberate in early 2027.
“The receipt of this approval marks a defining and highly significant milestone for Silexion,” stated Ilan Hadar, Chairman and Leader Govt Officer of Silexion Therapeutics. “We are now advancing SIL204 into a pivotal clinical trial with the goal of addressing KRAS-driven cancers at their source. This progress reflects the strength of our data, the safety demonstrated during the Loder (predecessor to SIL204) clinical trial, the urgency of the unmet need in pancreatic cancer, and our continued execution toward developing a potentially transformative therapy.”
About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology corporate devoted to the advance of leading edge therapies for unsatisfactorily handled forged tumor cancers that experience the mutated KRAS oncogene, typically thought to be to be the commonest oncogenic gene motive force in human cancers. The Corporate performed a Section 2a scientific trial in its first-generation product, which confirmed a good pattern compared to the regulate of chemotherapy on my own. Silexion is dedicated to pushing the limits of healing developments within the box of oncology and extra creating its lead product candidate for in the community complicated pancreatic most cancers. For more info, please talk over with: https://silexion.com
Understand Relating to Ahead-Having a look Statements:This press unencumber comprises forward-looking statements inside the that means of the federal securities regulations. All statements rather then statements of historic truth contained on this conversation, together with, for instance, statements in regards to the initiation, timing, design, and habits of the deliberate Section 2/3 scientific trial of SIL204, together with anticipated trial graduation in the second one quarter of 2026 and affected person enrollment; the timing, content material, and end result of regulatory submissions and interactions with regulatory government in Israel, Germany, the Ecu Union, and different jurisdictions; the development of SIL204 into clinical-stage building; the possible healing advantages and scientific application of SIL204 throughout KRAS-driven cancers; the Corporate’s plans to enlarge building into further indications, together with colorectal and lung cancers; the Corporate’s building technique and expected milestones; its skill to lift further capital and fund operations; and its skill to care for its Nasdaq list, are forward-looking statements. Those forward-looking statements are typically recognized via terminology similar to “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of those phrases or diversifications of them or identical terminology. Ahead-looking statements contain various dangers, uncertainties, and assumptions, and exact effects or occasions would possibly range materially from the ones projected or implied in the ones statements. Necessary components that might purpose such variations come with, however don’t seem to be restricted to: (i) Silexion’s skill to effectively entire preclinical research and start up scientific trials; (ii) Silexion’s technique, long run operations, monetary place, projected prices, potentialities, and plans; (iii) the have an effect on of the regulatory setting and compliance complexities; (iv) expectancies referring to long run partnerships or different relationships with 3rd events; (v) Silexion’s long run capital necessities and resources and makes use of of money, together with its skill to acquire further capital; (vi) Silexion’s skill to care for its Nasdaq list; and (vii) different dangers and uncertainties set forth within the paperwork filed via the Corporate with the SEC, together with the Corporate’s Annual Document on Shape 10-Okay for the yr ended December 31, 2025, filed with the SEC on March 17, 2026. Silexion cautions you in opposition to hanging undue reliance on forward-looking statements, which replicate present ideals and are in line with knowledge recently to be had as of the date a forward-looking observation is made. Ahead-looking statements set forth herein talk best as of the date they’re made. Silexion undertakes no legal responsibility to revise forward-looking statements to replicate long run occasions, adjustments in instances, or adjustments in ideals, excluding as another way required via legislation.
